Recipharm Wins SwedenBIO Award
The winner of the ninth annual SwedenBIO Award was announced on Thursday night (4th June). This year Recipharm AB was honoured for its efforts and contribution to Sweden life science during the past year.
The citation reads: "Recipharm has purposefully and with great skill built a solid organisation with a critical mass. A good revenue model has contributed to that the company created jobs in Sweden, but also established itself internationally. Recipharm is an extraordinary life science company that during the year strongly contributed to an increased interest in the industry and is an inspiring example for the whole of Swedish life science industry."
The prize is awarded to a company that demonstrated achievements and success beyond the norm in the life science industry in the past year and that has contributed to an increased interest in the business.
Lars Aldersson, Chairman of SwedenBIO said: “Recipharm shows that with the help of strong leadership, a responsible investment strategy and focus on quality it is possible to build a global life science company based in Sweden, something that will hopefully inspire others to similar deeds."
Thomas Eldered, CEO, commented: “We are very honoured to be recognized by SwedenBIO in this way. As an international company based in Sweden we are committed to investing and developing life science talent and capability here.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.